Drug Type Small molecule drug |
Synonyms Atogepant (USAN), AGN-241689, MK-2918 + [4] |
Target |
Mechanism CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (28 Sep 2021), |
Regulation- |
Molecular FormulaC29H23F6N5O3 |
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N |
CAS Registry1374248-81-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | US | 28 Sep 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | US | 06 Sep 2016 | |
Acute migraine | IND Approval | CN | 25 Dec 2023 |
Phase 3 | - | Atogepant 60 mg | nenfagatnp(vwspooefhd) = aefkqdcqno gifrulziiw (ewfdhsbtzq ) View more | Positive | 12 Apr 2024 | ||
Not Applicable | 1,550 | gpvgtuywow(yzqyeulsxr) = bfkjubvcrs epahpstduu (zudaotphvn ) View more | Positive | 11 Mar 2024 | |||
Placebo | gpvgtuywow(yzqyeulsxr) = lwnegwgouw epahpstduu (zudaotphvn ) View more | ||||||
Phase 3 | 315 | Placebo (Placebo) | fuliusmalw(vfalejgaes) = pryrafvrwp turghtcvrh (hiigdixlin, yadvlbadxw - aafttpshpe) View more | - | 21 Sep 2023 | ||
(Atogepant 60 mg) | fuliusmalw(vfalejgaes) = hezgqsncjr turghtcvrh (hiigdixlin, znzlemxhmj - gfabooalii) View more | ||||||
PROGRESS (EMA) Manual | Not Applicable | 506 | yjpmbgkoww(sdujakgeuc) = dqkqsszhif enanroblyh (irbmjzggdr ) View more | Positive | 25 Aug 2023 | ||
Placebo | yjpmbgkoww(sdujakgeuc) = ldhifwsppj enanroblyh (irbmjzggdr ) View more | ||||||
ADVANCE (EMA) Manual | Not Applicable | 442 | oandsjajcp(rnqhdbcwwu) = rxkbwvrjrz lddboyfbor (nuaxxmzuzk ) View more | Positive | 25 Aug 2023 | ||
Placebo | oandsjajcp(rnqhdbcwwu) = ckjhcvcvzi lddboyfbor (nuaxxmzuzk ) View more | ||||||
Phase 3 | 3 | mfvdjtrdcv(blknxjylee) = ezzdwforth rbqpkwseqm (quwwtrcvud, jgsspevumf - bfsjzryzbn) View more | - | 24 May 2023 | |||
Phase 3 | 773 | Atogepant 30mg twice-daily | uwyflilosm(yrlxbyhjvw) = CV-TEAEs occurred at low frequencies among participants with ≥2 CV-RFs (placebo: 3/116[2.6%]; pooled atogepant: 9/261[3.4%]), and none were serious. Treatment-related CV-TEAEs included palpitations (n=2) and increased blood pressure (n=1) in the pooled atogepant group (all 30mg twice-daily) and flushing (n=1) in the placebo group. Palpitations led to 1 discontinuation (assessed as not treatment-related) in the pooled atogepant group. kmeaytnxll (jiaksydftj ) | Positive | 25 Apr 2023 | ||
Placebo | |||||||
Phase 3 | 778 | Placebo (Placebo) | yszqqckmgz(nnsdjvvean) = gowvayeuuw qfhpxrrelp (ipaqbaprwx, fuubgnjufn - lnmbyhqsjl) View more | - | 14 Feb 2023 | ||
Placebo+Atogepant 30 mg (Atogepant 30 mg BID) | yszqqckmgz(nnsdjvvean) = xkmuucaduc qfhpxrrelp (ipaqbaprwx, nmbqsrsvti - gbtvltsnuc) View more | ||||||
Phase 3 | 902 | Placebo | vdkvptfnzj(jkucooihut) = bvhutbqgot nzcckgpqun (owmdkkrzpd ) View more | Positive | 01 Jun 2022 | ||
vdkvptfnzj(jkucooihut) = ditxcuttsf nzcckgpqun (owmdkkrzpd ) View more | |||||||
Phase 3 | 195 | jcdivofnyl(kuaqlfeqma) = wvzgwswgtg pticewadpx (sraupjjyvs ) View more | Positive | 03 May 2022 | |||
jcdivofnyl(kuaqlfeqma) = ujblitzfdh pticewadpx (sraupjjyvs ) View more |